月球生物工程(Lunai Bioworks)推出AI驱动的阿尔茨海默氏病临床预科计划,使用多模式数据将早期检测精确度提高35%。 Lunai Bioworks launches AI-driven Alzheimer’s preclinical program, boosting early detection accuracy by 35% using multi-modal data.

月球生物工程(Lunai Bioworks)利用AugustaTM AI平台启动了阿尔茨海默氏病临床预科计划,该平台将MRI、遗传和代谢数据结合起来,使诊断准确性比仅磁共振率提高35%。 Lunai Bioworks has launched a preclinical program for Alzheimer’s disease using its Augusta™ AI platform, which combines MRI, genetic, and metabolic data to boost diagnostic accuracy by up to 35% compared to MRI alone. 该平台经ADNI数据库验证后,利用分布式机器学习和云基基础设施分析多模式数据,使早期探测和可扩展的实时处理成为可能。 Validated on the ADNI database, the platform uses distributed machine learning and cloud-based infrastructure to analyze multi-modal data, enabling earlier detection and scalable, real-time processing. 该公司获得了第一份商业合同,以查明早期阿尔茨海默氏氏生物标志,并正在与研究机构和制药公司合作。 The company secured its first commercial contract to identify early Alzheimer’s biomarkers and is collaborating with research institutions and pharmaceutical firms. 这一方法以帕金森公司先前的工作为基础,反映了使用综合AI模型处理复杂的神经退化性疾病的更广泛战略。 The approach builds on prior work in Parkinson’s and reflects a broader strategy of using integrated AI models to address complex neurodegenerative diseases.